These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29101057)

  • 41. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
    Remon J; Menis J; Hasan B; Peric A; De Maio E; Novello S; Reck M; Berghmans T; Wasag B; Besse B; Dziadziuszko R
    Clin Lung Cancer; 2017 Sep; 18(5):583-588. PubMed ID: 28341106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
    Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
    Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
    Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
    Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
    Mezquita L; Varga A; Planchard D
    Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Lamb YN; Scott LJ
    Target Oncol; 2017 Aug; 12(4):555-562. PubMed ID: 28710746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
    Socinski MA; Villaruz LC; Ross J
    Oncologist; 2017 Jan; 22(1):3-11. PubMed ID: 27821794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
    Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Ariyasu R; Nishikawa S; Uchibori K; Oh-Hara T; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Kitazono S; Yanagitani N; Horiike A; Inase N; Kasahara K; Nishio M; Katayama R
    Lung Cancer; 2018 Mar; 117():1-6. PubMed ID: 29496249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
    Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Lemmon CA; Zabor EC; Pennell NA
    Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 57. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
    Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Nie K; Zhang Z; Zhang C; Geng C; Zhang L; Xu X; Liu S; Wang S; Zhuang X; Lan K; Ji Y
    Lung Cancer; 2018 Jul; 121():5-11. PubMed ID: 29858027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.